Adipose-derived mesenchymal stem cells for the prevention of capsular contracture.
Govrin-Yehudain O., Korzets Y., Zkika Y., Castel N., Brzezinski RY., Reuveni D.
Randomized Controlled Trial, published in J Mol Med (Berl) (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- J Mol Med (Berl) (2025)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40748384
- PMCID
- PMC12449375
- DOI
- 10.1007/s00109-025-02576-3
Abstract (original English)
Capsular contracture (CC) is the most common complication associated with implant-based breast surgery, with particularly high risk in patients undergoing alloplastic reconstruction surgery followed by radiation therapy. Revision surgery, the only currently effective treatment, carries a high risk of recurrent CC and secondary complications. This work assessed the prophylactic potential of human adipose-derived mesenchymal stem cells (hAD-MSCs) in a novel animal model of radiation-induced CC. A total of 36 female C57Bl/6 mice were randomly assigned to three groups: (1) IMP (silicone implants only), (2) IMP + RAD (silicone implants and irradiation therapy to promote CC), and (3) IMP + RAD + MSCs (silicone implants, irradiation therapy, and local administration of hAD-MSCs). On day 42 post-implantation, animals were euthanized and capsular tissue was subjected to histological and gene expression analyses. In addition, serum transforming growth factor beta (TGF-β) levels were measured. Targeted radiotherapy induced significant CC. In contrast, on day 42 post-irradiation, the capsular thickness in the IMP + RAD + MSCs group was significantly lower, comparable to that of non-irradiated mice. hAD-MSC treatment also resulted in a significant downregulation of pro-fibrotic and pro-inflammatory genes in the capsular tissue. In this study conducted in a murine model, hAD-MSCs demonstrate
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.